Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 2

Conditions

Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × loncastuximab tesirine × Other hematologic neoplasm × Clear all
NCT02669264 2021-05-24

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

ADC Therapeutics S.A.

Phase 1 Terminated
35 enrolled 31 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02669017 2021-05-19

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

ADC Therapeutics S.A.

Phase 1 Completed
183 enrolled 38 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡